S&P 500   3,818.10 (+1.32%)
DOW   31,335.61 (+1.33%)
QQQ   307.13 (+1.00%)
AAPL   120.23 (+0.08%)
MSFT   232.62 (+2.60%)
FB   261.09 (+1.34%)
GOOGL   2,074.41 (+1.99%)
TSLA   596.80 (-3.96%)
AMZN   2,984.83 (+0.24%)
NVDA   495.89 (+0.22%)
BABA   233.36 (+1.24%)
CGC   30.82 (-0.61%)
GE   13.50 (-0.52%)
MU   88.52 (+4.97%)
NIO   37.03 (-5.73%)
AMD   78.21 (+0.59%)
T   29.51 (+2.04%)
F   12.13 (+1.68%)
ACB   9.39 (-4.38%)
DIS   188.22 (+0.10%)
BA   220.30 (-1.96%)
NFLX   512.52 (+0.24%)
BAC   36.65 (+0.41%)
S&P 500   3,818.10 (+1.32%)
DOW   31,335.61 (+1.33%)
QQQ   307.13 (+1.00%)
AAPL   120.23 (+0.08%)
MSFT   232.62 (+2.60%)
FB   261.09 (+1.34%)
GOOGL   2,074.41 (+1.99%)
TSLA   596.80 (-3.96%)
AMZN   2,984.83 (+0.24%)
NVDA   495.89 (+0.22%)
BABA   233.36 (+1.24%)
CGC   30.82 (-0.61%)
GE   13.50 (-0.52%)
MU   88.52 (+4.97%)
NIO   37.03 (-5.73%)
AMD   78.21 (+0.59%)
T   29.51 (+2.04%)
F   12.13 (+1.68%)
ACB   9.39 (-4.38%)
DIS   188.22 (+0.10%)
BA   220.30 (-1.96%)
NFLX   512.52 (+0.24%)
BAC   36.65 (+0.41%)
S&P 500   3,818.10 (+1.32%)
DOW   31,335.61 (+1.33%)
QQQ   307.13 (+1.00%)
AAPL   120.23 (+0.08%)
MSFT   232.62 (+2.60%)
FB   261.09 (+1.34%)
GOOGL   2,074.41 (+1.99%)
TSLA   596.80 (-3.96%)
AMZN   2,984.83 (+0.24%)
NVDA   495.89 (+0.22%)
BABA   233.36 (+1.24%)
CGC   30.82 (-0.61%)
GE   13.50 (-0.52%)
MU   88.52 (+4.97%)
NIO   37.03 (-5.73%)
AMD   78.21 (+0.59%)
T   29.51 (+2.04%)
F   12.13 (+1.68%)
ACB   9.39 (-4.38%)
DIS   188.22 (+0.10%)
BA   220.30 (-1.96%)
NFLX   512.52 (+0.24%)
BAC   36.65 (+0.41%)
S&P 500   3,818.10 (+1.32%)
DOW   31,335.61 (+1.33%)
QQQ   307.13 (+1.00%)
AAPL   120.23 (+0.08%)
MSFT   232.62 (+2.60%)
FB   261.09 (+1.34%)
GOOGL   2,074.41 (+1.99%)
TSLA   596.80 (-3.96%)
AMZN   2,984.83 (+0.24%)
NVDA   495.89 (+0.22%)
BABA   233.36 (+1.24%)
CGC   30.82 (-0.61%)
GE   13.50 (-0.52%)
MU   88.52 (+4.97%)
NIO   37.03 (-5.73%)
AMD   78.21 (+0.59%)
T   29.51 (+2.04%)
F   12.13 (+1.68%)
ACB   9.39 (-4.38%)
DIS   188.22 (+0.10%)
BA   220.30 (-1.96%)
NFLX   512.52 (+0.24%)
BAC   36.65 (+0.41%)
Log in
NASDAQ:ASNS

Arsanis Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$3.11
0.00 (0.00 %)
(As of 03/13/2019)
Add
Compare
Today's Range
$3.05
Now: $3.11
$3.78
50-Day Range
$3.11
MA: $3.11
$3.11
52-Week Range
$1.15
Now: $3.11
$28.69
Volume607,244 shs
Average Volume62,844 shs
Market Capitalization$45.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.
Arsanis logo

Headlines

X4 Pharmaceuticals: An Overview
November 14, 2019 |  seekingalpha.com
X4 Pharmaceuticals Completes Merger with Arsanis
March 13, 2019 |  www.businesswire.com
Arsanis, Inc. (ASNS)
January 26, 2019 |  seekingalpha.com
Arsanis files $150M mixed shelf
January 26, 2019 |  seekingalpha.com
Arsanis Inc.
December 13, 2018 |  www.barrons.com
See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASNS
CUSIPN/A
Phone(857) 529-8300
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.50 million
Book Value$4.29 per share

Profitability

Net Income$-33,870,000.00

Miscellaneous

Market Cap$45.53 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

1.07 out of 5 stars

Medical Sector

985th out of 1,972 stocks

Biotechnology Industry

30th out of 125 stocks

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Receive ASNS News and Ratings via Email

Sign-up to receive the latest news and ratings for ASNS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arsanis (NASDAQ:ASNS) Frequently Asked Questions

What stocks does MarketBeat like better than Arsanis?

Wall Street analysts have given Arsanis a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arsanis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Arsanis' earnings last quarter?

Arsanis, Inc. (NASDAQ:ASNS) announced its earnings results on Friday, November, 9th. The company reported ($0.76) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.02.
View Arsanis' earnings history
.

Who are Arsanis' key executives?

Arsanis' management team includes the following people:
  • Paula S. Ragan, President, Chief Executive Officer & Director
  • Adam S. Mostafa, Chief Financial Officer & Treasurer
  • Celeste DiJohnson, Vice President-Clinical Operations
  • Mary DiBiase, Vice President-Technical Operations & Quality
  • Tarek Ebrahim, Vice President-Medical Affairs & Rare Disease

Who are some of Arsanis' key competitors?

What other stocks do shareholders of Arsanis own?

When did Arsanis IPO?

(ASNS) raised $50 million in an initial public offering on Thursday, November 16th 2017. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Citigroup, Cowen and Piper Jaffray served as the underwriters for the IPO.

What is Arsanis' stock symbol?

Arsanis trades on the NASDAQ under the ticker symbol "ASNS."

What is Arsanis' stock price today?

One share of ASNS stock can currently be purchased for approximately $3.11.

How much money does Arsanis make?

Arsanis has a market capitalization of $45.53 million and generates $3.50 million in revenue each year. The company earns $-33,870,000.00 in net income (profit) each year or ($16.23) on an earnings per share basis.

What is Arsanis' official website?

The official website for Arsanis is www.arsanis.com.

Where are Arsanis' headquarters?

Arsanis is headquartered at 890 WINTER STREET SUITE 230, WALTHAM MA, 02451.

How can I contact Arsanis?

Arsanis' mailing address is 890 WINTER STREET SUITE 230, WALTHAM MA, 02451. The company can be reached via phone at (857) 529-8300 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.